ESPR
Esperion Therapeutics Inc
3.20$
+0.0%
vs. previous close
Closing price · As of: Jul 15, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 1999 | 2000 | 2001 | 2002 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | -100.0% | – | – | – | – | -19.6% | +53.4% | -65.5% | -3.8% | +54.1% | +185.7% | +21.3% | |
| – | +15.0% | – | – | – | – | – | – | – | +6.8% | +2.4% | +66,368.2% | +2.4% | -98.6% | +494.4% | +89.7% | +60.4% | +58.6% | +88.4% | |
| – | – | – | – | – | – | – | -100.0% | – | – | – | – | -19.6% | +51.8% | -71.5% | -24.5% | +50.6% | +260.9% | +3.9% | |
| – | +156.8% | -1.5% | +2.5% | -64.5% | +2.4% | +100.2% | +58.0% | +17.8% | +94.2% | +155.1% | +16.2% | +2.4% | -16.3% | -27.9% | +12.2% | -27.6% | -46.3% | +3.5% | |
| – | – | – | – | – | -6.4% | +205.8% | +61.9% | +85.3% | -9.7% | +16.9% | +54.8% | +99.0% | +173.8% | -5.0% | -42.9% | +29.8% | +8.4% | +20.5% | |
| – | +129.2% | +9.5% | -0.3% | -65.2% | +0.4% | +123.0% | +59.2% | +38.1% | +52.2% | +121.9% | +21.1% | +18.0% | +43.5% | -16.0% | -21.6% | +0.3% | -8.4% | +2.1% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +10.8% | |
| – | – | – | – | – | +157.6% | -37.0% | -71.2% | +92.6% | -27.7% | -47.3% | -49.5% | +8,020.0% | +179.2% | +104.5% | +22.6% | +3.8% | +0.5% | +42.8% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | -88.6% | +342.5% | -75.8% | +179.9% | -19.4% | -79.7% | +362.9% | +57.7% | +27.5% | +34.8% | +312.4% | +90.9% | +119.6% | +8.9% | -100.0% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +743.8% |
Data as of: July 15, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.